Jing Tian Biotech's Two Major New Drugs Enter Mid-to-Late Stage Clinical Trials, Aiming for Licensing Cooperation
Jing Tian Biotech's two new drugs, APC101 pain relief spray and APC201 anti-inflammatory foam, have entered mid-to-late stage clinical trials. International pharmaceutical companies have proactively inquired about cooperation opportunities. The company is pursuing a dual-engine strategy of new drug licensing and co-development to expand its operations.
📋 Article Processing Timeline
- 📰 Published: April 15, 2026 at 19:51
- 🔍 Collected: April 15, 2026 at 20:01 (10 min after Published)
- 🤖 AI Analyzed: April 15, 2026 at 20:23 (21 min after Collected)
Central News Agency
(Central News Agency reporter He Xiuling, Taipei, April 15) Jing Tian Biotech Chairman Wang Aijun stated today that market demand for next-generation precision pain management solutions is expected to grow rapidly. The company's two major new drug candidates, APC101 pain relief spray and APC201 anti-inflammatory foam, have both entered mid-to-late stage clinical trials. International pharmaceutical companies have already proactively inquired, and evaluations and subsequent cooperation opportunities are underway.
Wang Aijun pointed out that this year, the company will continue to adopt a dual-engine strategy of new drug licensing and co-development to expand its operational footprint. Several cooperation cases are currently under negotiation, with clarity expected in the second half of the year, leading to an optimistic outlook for the full year.
Jing Tian Biotech primarily focuses on the development of new topical drug formulations, with Yongguang Chemical as its major shareholder. A media exchange meeting was held today. Regarding the two new drugs, Wang Aijun said that APC101 is a new spray drug for relieving postherpetic neuralgia (PHN). It has been approved for Phase 2b and Phase 3 clinical trials in Australia and the United States and will initiate multinational patient recruitment. If approved for market, it may extend to other pain treatment areas, expanding its indications.
She added that another new drug, APC201, is a topical medication for treating local pain in knee osteoarthritis (OA). Phase 1 and Phase 2a clinical trials have been completed, and global multi-center Phase 2b and Phase 3 clinical trials are being planned.
Benefiting from effective marketing strategies and revenue from co-development licensing fees, Jing Tian Biotech's Q1 revenue this year was NT$4.345 million, surpassing the cumulative revenue of NT$4.32 million for the first 11 months of last year. (Editor: Yang Lanxuan) 1150415
Choose to stand with facts, every sponsorship you make is a force to protect press freedom.
Download the Central News Agency 'First-hand News' APP to stay updated with the latest news.
The text, images, and videos on this website may not be reproduced, publicly broadcast, or publicly transmitted and used without authorization.
(Central News Agency reporter He Xiuling, Taipei, April 15) Jing Tian Biotech Chairman Wang Aijun stated today that market demand for next-generation precision pain management solutions is expected to grow rapidly. The company's two major new drug candidates, APC101 pain relief spray and APC201 anti-inflammatory foam, have both entered mid-to-late stage clinical trials. International pharmaceutical companies have already proactively inquired, and evaluations and subsequent cooperation opportunities are underway.
Wang Aijun pointed out that this year, the company will continue to adopt a dual-engine strategy of new drug licensing and co-development to expand its operational footprint. Several cooperation cases are currently under negotiation, with clarity expected in the second half of the year, leading to an optimistic outlook for the full year.
Jing Tian Biotech primarily focuses on the development of new topical drug formulations, with Yongguang Chemical as its major shareholder. A media exchange meeting was held today. Regarding the two new drugs, Wang Aijun said that APC101 is a new spray drug for relieving postherpetic neuralgia (PHN). It has been approved for Phase 2b and Phase 3 clinical trials in Australia and the United States and will initiate multinational patient recruitment. If approved for market, it may extend to other pain treatment areas, expanding its indications.
She added that another new drug, APC201, is a topical medication for treating local pain in knee osteoarthritis (OA). Phase 1 and Phase 2a clinical trials have been completed, and global multi-center Phase 2b and Phase 3 clinical trials are being planned.
Benefiting from effective marketing strategies and revenue from co-development licensing fees, Jing Tian Biotech's Q1 revenue this year was NT$4.345 million, surpassing the cumulative revenue of NT$4.32 million for the first 11 months of last year. (Editor: Yang Lanxuan) 1150415
Choose to stand with facts, every sponsorship you make is a force to protect press freedom.
Download the Central News Agency 'First-hand News' APP to stay updated with the latest news.
The text, images, and videos on this website may not be reproduced, publicly broadcast, or publicly transmitted and used without authorization.
FAQ
What new drugs is Jing Tian Biotech developing?
Jing Tian Biotech is developing two new drugs: APC101 pain relief spray and APC201 anti-inflammatory foam.
What stage are Jing Tian Biotech's new drugs in?
Both new drugs are in mid-to-late stage clinical trials, with APC101 in Phase 2b and Phase 3, and APC201 planning global multi-center Phase 2b and Phase 3 clinical trials.